Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical equipment in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and eye vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. The company was founded in 1965 and is headquartered in Seoul, South Korea.
Hyundai Pharmaceutical Dividend Announcement
• Hyundai Pharmaceutical announced a semi annually dividend of ₩35.00 per ordinary share which will be made payable on . Ex dividend date: 2024-03-05
• Hyundai Pharmaceutical annual dividend for 2024 was ₩35.00
• Hyundai Pharmaceutical's trailing twelve-month (TTM) dividend yield is 1.06%
• Hyundai Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 94.93%
Hyundai Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-03-05 | ₩35.00 | semi annually | |
2022-12-28 | ₩30.00 | semi annually | |
2022-11-29 | ₩30.00 | semi annually | 2023-03-22 |
2021-12-29 | ₩30.00 | semi annually | |
2021-11-29 | ₩30.00 | semi annually | 2022-03-23 |
2020-11-27 | ₩42.50 | semi annually | 2021-03-23 |
2019-11-28 | ₩45.00 | semi annually | 2020-03-18 |
2018-11-29 | ₩45.00 | semi annually | 2019-03-06 |
2017-11-29 | ₩50.00 | semi annually | 2018-03-02 |
2016-11-29 | ₩46.27 | semi annually | |
2015-11-27 | ₩46.27 | semi annually | |
2014-11-27 | ₩43.84 | semi annually | |
2013-11-28 | ₩41.40 | semi annually | |
2012-11-29 | ₩36.53 | semi annually |
Hyundai Pharmaceutical Dividend per year
Hyundai Pharmaceutical Dividend growth
Hyundai Pharmaceutical Dividend Yield
Hyundai Pharmaceutical current trailing twelve-month (TTM) dividend yield is 1.06%. Interested in purchasing Hyundai Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Hyundai Pharmaceutical Financial Ratios
Hyundai Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Hyundai Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Hyundai Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Hyundai Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Hyundai Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Hyundai Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Hyundai Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Hyundai Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Hyundai Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Hyundai Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Hyundai Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Hyundai Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.